文献类型：期刊文献

英文题名：Anti-vascular endothelial growth factor drugs for treatment of diabetes retinopathy: an umbrella review; [抗VEGF药物治疗糖尿病视网膜病变的伞状系统评价]

作者：Ling J.; Guan J.; Luo X.; Xe Z.; Luo X.

第一作者：Ling J.

机构：[1]Gansu University of Chinese Medicine, Gansu Province, Lanzhou, 730030, China;[2]Gansu Provincial Hospital, Gansu Province, Lanzhou, 730030, China;[3]Gansu Provincial Hospital of Traditional Chinese Medicine, Gansu Province, Lanzhou, 130050, China;[4]Evidence-Based Medicine Center of Lanzhou University, Gansu Province, Lanzhou, 130030, China

第一机构：甘肃中医药大学

年份：2025

卷号：45

期号：2

起止页码：108

外文期刊名：Recent Advances in Ophthalmology

收录：Scopus(收录号：2-s2.0-85217207707)

语种：英文

外文关键词：AMSTAR 2; anti-vascular endothelial growth factor; diabetes retinopathy; PRISMA; umbrella review

摘要：Objective To conduct an umbrella review of systematic studies/meta-analyses of anti-vascular endothelial growth factor (VEGF) drugs for the treatment of diabetes retinopathy (DR), to evaluate literature quality with AMSTAR 2 and PRISMA, and to show the distribution characteristics of evidence quality through both figures and tables. Methods Chinese and English databases including The Cochrane Library, PubMed, EMbase, CBM, Wanfang, and CNKI were searched on computer from the inception of the database up to March 2024 for the retrieval of systematic re vie ws/meta-analyses on anti-VEGF drug therapy for DR treatment. Two evaluators read the literature and extract data separately before conducting an umbrella review of the methodological and reporting quality of the included literature using the AMSTAR 2 scale and PRISMA statement. Results 27 studies were ultimately included, and the methodological and reporting quality of systematic revie ws/meta-analyses on anti-VEGF drugs for DR treatment was moderate-to-low. The evaluation by AMSTAR 2 showed that there was an urgent need to improve the elaboration of the pre-established research plan and funding sources included in the research. PRISMA results showed that items affecting reporting quality mainly included protocol and registration, literature search, supplementary analysis, and funding sources. Conclusion The methodological and reporting quality of systematic reviews/meta-analyses on anti-VEGF drug therapy for DR treatment needs to be improved. Researchers should strengthen methodological quality and reporting standards following the requirements of the AMSTAR 2 scale and PRISMA statement while writing systematic revie ws/meta-analysis reports, so as to provide evidence with higher quality. ? 2025 Xinxiang Medical University. All rights reserved.